GetTopicDetailResponse(id=e91e10469f7, topicName=Keytruda, introduction=Keytruda, content=null, image=null, comments=3, allHits=3172, url=https://h5.medsci.cn/topic?id=10469, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=32964, tagList=[TagDto(tagId=32964, tagName=Keytruda)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2118396, encodeId=a0b52118396c9, content=<a href='/topic/show?id=795b10549832' target=_blank style='color:#2F92EE;'>#MK-4280A#</a>是一種由<a href='/topic/show?id=67c61046e460' target=_blank style='color:#2F92EE;'>#LAG-3#</a>抗體<a href='/topic/show?id=845c1054990d' target=_blank style='color:#2F92EE;'>#Favezelimab#</a>（MK-4280）和PD-1抑制劑<a href='/topic/show?id=e91e10469f7' target=_blank style='color:#2F92EE;'>#Keytruda#</a>的聯(lián)合治療方案，其中Favezelimab能夠阻斷MHCII類受體與LAG-3之間的相互作用，抑制LAG-3上調(diào)，進(jìn)而恢復(fù)T細(xì)胞對(duì)<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#腫瘤#</a>細(xì)胞的殺傷效應(yīng)。<a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠單抗#</a>, objectTitle=LAG-3：腫瘤免疫治療中新一代治療靶點(diǎn), objectType=article, longId=294891, objectId=6743294891fb, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=6743294891fb, replyNumber=0, likeNumber=160, createdTime=2023-03-09, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6743294891fb, moduleTitle=LAG-3：腫瘤免疫治療中新一代治療靶點(diǎn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6743294891fb)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=899586, encodeId=ec4d89958671, content=<a href='/topic/show?id=e91e10469f7' target=_blank style='color:#2F92EE;'>#Keytruda#</a>與<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化療#</a>聯(lián)合一線治療轉(zhuǎn)移性<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三陰性乳腺癌#</a>TNBC，只是效果仍然不理想，雖然療效整體有提升。其實(shí)T藥也是一樣，雖然有療效，整體仍然不滿意。三陰性乳腺癌仍然是一座大山！探索新的化療模式，仍然是重要的。, objectTitle=默克PD-1單抗Keytruda：獲得FDA批準(zhǔn)首個(gè)乳腺癌適應(yīng)癥, objectType=article, longId=203465, objectId=f0b620346555, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201113/9b665370fb054258bf3c92ec7500ee85.jpg, objectUrl=/article/show_article.do?id=f0b620346555, replyNumber=0, likeNumber=328, createdTime=2020-11-16, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b620346555, moduleTitle=默克PD-1單抗Keytruda：獲得FDA批準(zhǔn)首個(gè)乳腺癌適應(yīng)癥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f0b620346555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=602429, encodeId=68ad6024299a, content=<a href='/topic/show?id=e91e10469f7' target=_blank style='color:#2F92EE;'>#Keytruda#</a>跨瘤種，是趨勢(shì), objectTitle=FDA批準(zhǔn)PD-1單抗Keytruda的第二種基于生物標(biāo)志物的腫瘤適應(yīng)癥, objectType=article, longId=196062, objectId=59a819606271, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200617/186ed7a0d6314a2798fe6446141fd7a2.jpg, objectUrl=/article/show_article.do?id=59a819606271, replyNumber=0, likeNumber=211, createdTime=2020-06-17, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59a819606271, moduleTitle=FDA批準(zhǔn)PD-1單抗Keytruda的第二種基于生物標(biāo)志物的腫瘤適應(yīng)癥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=59a819606271)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
